The approval of a new oral postexposure prophylaxis for COVID-19 marks a significant advancement in the disease's prevention ...
FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...
Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results